Literature DB >> 15210993

Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding.

Qing Huai1, Huanchen Wang, Wei Zhang, Robert W Colman, Howard Robinson, Hengming Ke.   

Abstract

Cyclic nucleotide phosphodiesterases (PDEs) are enzymes controlling cellular concentrations of the second messengers cAMP and cGMP. The crystal structure of the catalytic domain of PDE9A2, a member of a PDE family specifically hydrolyzing cGMP, has been determined at 2.23-A resolution. The PDE9A2 catalytic domain closely resembles the cAMP-specific PDE4D2 but is significantly different from the cGMP-specific PDE5A1, implying that each individual PDE family has its own characteristic substrate recognition mechanism. The different conformations of the H and M loops between PDE9A2 and PDE5A1 imply their less critical roles in nucleotide recognition. The nonselective inhibitor 3-isobutyl-1-methylxanthine (IBMX) binds to a similar subpocket in the active sites of PDE4, PDE5, and PDE9 and has a common pattern of the binding. However, significantly different orientations and interactions of IBMXs are observed among the three PDE families and also between two monomers of the PDE9A2 dimer. The kinetic properties of the PDE9A2 catalytic domain similar to those of full-length PDE9A imply that the N-terminal regulatory domain does not significantly alter the catalytic activity and the IBMX inhibition.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210993      PMCID: PMC470725          DOI: 10.1073/pnas.0401120101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in heart failure.

Authors:  M A Movsesian
Journal:  Expert Opin Investig Drugs       Date:  2000-05       Impact factor: 6.206

Review 2.  The next generation of PDE4 inhibitors.

Authors:  Z Huang; Y Ducharme; D Macdonald; A Robichaud
Journal:  Curr Opin Chem Biol       Date:  2001-08       Impact factor: 8.822

Review 3.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 4.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions.

Authors:  S H Soderling; J A Beavo
Journal:  Curr Opin Cell Biol       Date:  2000-04       Impact factor: 8.382

Review 5.  Cyclic GMP phosphodiesterase-5: target of sildenafil.

Authors:  J D Corbin; S H Francis
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

6.  Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity.

Authors:  R X Xu; A M Hassell; D Vanderwall; M H Lambert; W D Holmes; M A Luther; W J Rocque; M V Milburn; Y Zhao; H Ke; R T Nolte
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

Review 7.  Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.

Authors:  M C Truss; C G Stief; S Uckert; A J Becker; J Wefer; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

Review 8.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Authors:  Y Liu; Y Shakur; M Yoshitake; J Kambayashi Ji
Journal:  Cardiovasc Drug Rev       Date:  2001

Review 9.  Pharmacology of phosphodiesterase-5 inhibitors.

Authors:  J D Corbin; S H Francis
Journal:  Int J Clin Pract       Date:  2002 Jul-Aug       Impact factor: 2.503

Review 10.  Phosphodiesterase 5 inhibitors: current status and potential applications.

Authors:  David P Rotella
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

View more
  29 in total

1.  Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor.

Authors:  Manna Huang; Yongxian Shao; Jianying Hou; Wenjun Cui; Beibei Liang; Yingchun Huang; Zhe Li; Yinuo Wu; Xinhai Zhu; Peiqing Liu; Yiqian Wan; Hengming Ke; Hai-Bin Luo
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

2.  Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Authors:  Shenping Liu; Mahmoud N Mansour; Keith S Dillman; Jose R Perez; Dennis E Danley; Paul A Aeed; Samuel P Simons; Peter K Lemotte; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

3.  Determinants for phosphodiesterase 6 inhibition by its gamma-subunit.

Authors:  Zhongming Zhang; Nikolai O Artemyev
Journal:  Biochemistry       Date:  2010-05-11       Impact factor: 3.162

4.  Phosphodiesterase inhibitors as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that are highly conserved between host and parasite.

Authors:  Thomas Seebeck; Geert Jan Sterk; Hengming Ke
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

6.  Identification of new PDE9A isoforms and how their expression and subcellular compartmentalization in the brain change across the life span.

Authors:  Neema S Patel; Jennifer Klett; Katy Pilarzyk; Dong Ik Lee; David Kass; Frank S Menniti; Michy P Kelly
Journal:  Neurobiol Aging       Date:  2018-02-05       Impact factor: 4.673

7.  Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain.

Authors:  Zier Yan; Huanchen Wang; Jiwen Cai; Hengming Ke
Journal:  Protein Expr Purif       Date:  2008-10-19       Impact factor: 1.650

8.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Authors:  Qing Huai; Yingjie Sun; Huanchen Wang; Dwight Macdonald; Renée Aspiotis; Howard Robinson; Zheng Huang; Hengming Ke
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

9.  Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte.

Authors:  Rachael P Norris; William J Ratzan; Marina Freudzon; Lisa M Mehlmann; Judith Krall; Matthew A Movsesian; Huanchen Wang; Hengming Ke; Viacheslav O Nikolaev; Laurinda A Jaffe
Journal:  Development       Date:  2009-06       Impact factor: 6.868

10.  Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct.

Authors:  Jayvardhan Pandit; Michael D Forman; Kimberly F Fennell; Keith S Dillman; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.